The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

singularmedical.net

Founded Year

2017

Stage

Series B | Alive

Total Raised

$24M

Last Raised

$14M | 1 yr ago

About Singular Medical

Singular Medical specializes in the development, production, and sales of implantable cardioverter defibrillator, cardiac pacemaker, cardiac pacemaker, and other cardiac rhythm management (CRM) products.

Singular Medical Headquarter Location

3rd Floor, Building 18, No. 8 Jinfeng Road, High-tech Zone

Suzhou, Jiangsu,

China

+86-512-65837523

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Singular Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Singular Medical is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

Latest Singular Medical News

China Digest: Drugmaker Sciwind bags $39m; Qiming backs Singular Medical

Feb 19, 2021

Source:Jan Antonin Kolar/Unsplash February 19, 2021 Drugmaker Sciwind has closed a $39 million Series B round led by LYFE Capital, while SDIC Unity Capital and Qiming Venture Partners have co-led a Series B round funding in Singular Medical. Drugmaker Sciwind bags $39m Series B Clinical-stage innovative drugmaker Sciwind on Friday announced the completion of a Series B round financing raising 250 million yuan ($39 million) led by LYFE Capital, a healthcare fund that primarily invests in China and the US. Lenovo Holdings’ investment arm Legend Capital and Zhejiang Haibang Investment Management re-upped in the current round, the investee said in a WeChat post. Legend Capital along with Lenovo Holdings, Shenzhen Shiyu Investment Management, and the liver-focused pharmaceutical firm Beijing Kawin Technology Share-Holding had together invested nearly 200 million yuan ($30 million) in Sciwind’s Series A round in 2019. Prior to that, in 2018, Haibang Investment and Shiyu Investment joined hands to pump capital into Sciwind’s Pre-A round. Set up in 2017, in East China’s Hangzhou city, Sciwind is a clinical-stage pharmaceutical firm producing macromolecule-based medicines for chronic metabolic diseases, and immunopathy. “The proceeds of the round will give impetus to the development of clinical programmes, besides facilitating our… drug candidates entering to clinical phases. Additionally, it will support us to further advance talent recruits,” said founder and CEO Hai Pan. Qiming co-leads Series B funding in Singular Medical Medical equipment maker Suzhou Singular Medical Co., Ltd has pocketed ‘tens of millions of US dollars’ in a Series B round jointly led by new investor SDIC Unity Capital, an investment vehicle of State Development & Investment. Qiming Venture Partners, which co-led the current round, is an existing investor. Other returning backers participated in the round including early-stage Northern Light Venture Capital, state-backed SND Ventures Group, and healthcare fund Marathon Venture Partners. Investment bank Das Capital facilitated the transaction, Qiming announced on Friday. Singular Medical will use the funds to support talent recruits, clinical trials, and pipeline products. With headquarters in Suzhou and R&D centres in Beijing and US Irvine, Singular Medical specialises in the R&D of cardiac rhythm management (CRM) products covering diagnosis, treatment, and monitor. Its offerings consist of implantable cardioverter defibrillator (ICD), insertabile cardiac monitor (ICM), and implantable cardiac resynchronization therapy (CRT) defibrillator (CRT-D), among others. Before the latest round, Qiming, Northern Light, SND Ventures and Marathon Venture had teamed up seeding a similar-sized sum for Singular Medical’s Series A round in March 2020. Earlier in 2017, ZhenFund had exclusively invested in its Seed round. Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday REGISTER 1You have one free story left this month.You have 1 free stories left this month.This is your last free story of the month. Register to continue reading our free content. × We will never share your information with third parties. If you don’t already have an account click the button below to create your account. Join DealstreetAsia's premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.